The phased rollout
Pharmaceutical tariffs are taking effect in phases through September 2026, part of a wider period of tariff turbulence affecting global trade. For healthcare and life sciences supply chains, this adds cost and complexity on top of already tight regulatory margins.
Where the impact lands hardest
Organisations sourcing active ingredients or finished products from tariff-affected regions face the sharpest cost pressure, particularly where contracts were priced before the phased tariffs were confirmed. Fixed-price supply agreements signed earlier in the year may no longer reflect actual landed cost.
Contingency actions worth taking now
Revisit pricing clauses in active pharmaceutical and medical supply contracts to check how tariff pass-through is handled, and confirm whether alternative, tariff-exempt supply routes exist for critical products. Waiting until margins are visibly squeezed removes the time needed to requalify an alternative source.
Back to Insights